Latest from the Blog
Prosciens is a Luxembourg-based contract research scientific company. We are experts on molecular modelling with a focus on the biopharmaceutical sector. Our business model encompasses two main axes: 1.- Providing state-of-the-art scientific services; and 2.- Developing our own research portfolio.
Our areas of expertise include the following structure-based technologies: de novo drug design, virtual screening, reverse virtual screening, lead optimisation, retrosynthetic analysis, homology modelling, multi-resolution modelling, molecular simulations and computational chemistry.
Prosciens internal portfolio currently consists of three main projects: 1.- Cancer metabolism: We are currently exploring the therapeutic potential of Warburg effect. 2.- Neurodegenerative diseases: We are starting to explore the therapeutic potential of microtubule stabilisation. 3.- Covalent COX inhibitors.